Palvella Therapeutics (PVLA) Liabilities and Shareholders Equity (2013 - 2026)

Palvella Therapeutics (PVLA) has 14 years of Liabilities and Shareholders Equity data on file, last reported at $263.8 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $263.8 million, up 232.03% year-over-year; the trailing twelve-month figure through Mar 2026 was $464.0 million (up 117.59% YoY), and the FY2025 annual result was $59.6 million, down 32.5% from the prior year.
• Liabilities and Shareholders Equity advanced to $263.8 million in Q1 2026 per PVLA's latest filing, from $59.6 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $263.8 million in Q1 2026 and troughed at $7.5 million in Q4 2023.
• A 5-year average of $81.7 million and a median of $79.4 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity plunged 92.1% in 2023, then surged 1068.97% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $95.5 million in 2022, then sank by 92.1% to $7.5 million in 2023, then surged by 1068.97% to $88.2 million in 2024, then slumped by 32.5% to $59.6 million in 2025, then soared by 342.85% to $263.8 million in 2026.
• Business Quant data shows PVLA's Liabilities and Shareholders Equity at $263.8 million in Q1 2026, $59.6 million in Q4 2025, and $66.9 million in Q3 2025.